



**FOR IMMEDIATE RELEASE**

**LAUREATE PHARMA ANNOUNCES AGREEMENT WITH TRUBION PHARMACEUTICALS**

**-LAUREATE TO MANUFACTURE TRUBION'S TRU-016 PRODUCT CANDIDATE-**

**Princeton, NJ, January 30, 2007** -- Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced it has entered into an agreement to produce Trubion Pharmaceuticals, Inc.'s TRU-016, a novel protein for the treatment of non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Terms of the manufacturing agreement were not disclosed.

Trubion's TRU-016 program targets CD37, an antigen present on B cells, for the treatment of NHL and CLL. Subject to satisfactory completion of preclinical testing of TRU-016, the Company expects to file an IND for TRU-016 in the second half of 2007. Trubion currently retains all development and commercialization rights for the TRU-016 program.

"We are pleased that Trubion chose Laureate Pharma to manufacture TRU-016 for preclinical and clinical testing," notes Robert J. Broeze, Ph.D., President and Chief Executive Officer of Laureate Pharma, "and we look forward to working with them on this novel product."

**About Laureate Pharma, Inc.**

Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. Laureate Pharma, Inc. is a partner company of Safeguard Scientifics, Inc. (NYSE: SFE), which builds value in high-growth, revenue stage information technology and life sciences businesses ([www.safeguard.com](http://www.safeguard.com).) For more information, contact Michael Cavanaugh, Vice President Sales, Marketing, and Business Development at (609) 919-3400, or [info@laureatepharma.com](mailto:info@laureatepharma.com) or visit [www.laureatepharma.com](http://www.laureatepharma.com).